• Recce signs CRADA with the U.S. Army Institute of Surgical Research (USAISR) to evaluate RECCE® 327 Gel (R327G) in reducing bioburden of burn wounds
• Study will assess R327G's effectiveness against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa, major burn wound pathogens
• Builds on Recce's first CRADA with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)

Recce Pharmaceuticals has announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Institute of Surgical Research (USAISR), a world leader in studying combat casualty research and burn care. Under this agreement, USAISR will evaluate Recce's topical formulation, RECCE® 327 Gel (R327G), in their validated Walker-Mason rat model of burn wound infection. The study aims to assess whether R327G can significantly reduce bacterial burden in infected burn wounds, specifically against Methicillin-Resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, two major pathogens frequently isolated from burn patients. Burn wound infections remain one of the leading causes of mortality in burn patients and are clinically difficult to manage due to the growing challenge of antimicrobial resistance. R327G, a broad-spectrum synthetic anti-infective, is being developed as a next-generation amorphous gel wound dressing and is expected to offer practical utility for frontline deployment in military field kits, as well as potential application in clinical settings and post-operative care. This new agreement, together with Recce's existing collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), and the recent CDMRP grant award, demonstrates the accelerating U.S. Government interest in R327 across multiple operational and therapeutic applications.

The study with USAISR will evaluate whether R327G can effectively reduce the bioburden of Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa, two clinically significant bacterial pathogens associated with burn wound infections. This marks Recce's R327G potential for supporting practical field deployment as a hydrogel wound dressing, with potential broader clinical and post-operative application.